ICER had previously said that a ‘fair’ price for Relyvrio would be between $9,100 and $30,000 per year. Currently, the ALS drug is priced about five times higher than the top of a value-based ...

Amylyx stock crashed Friday, losing almost all of its value, after the company said its approved ALS treatment, Relyvrio, failed in a pivotal study. Please watch the video at Investors.com - How ...

Amylyx confirmed today that it will withdraw its amyotrophic lateral sclerosis (ALS) therapy Relyvrio/Albrioza from the market in the US and Canada, shortly after the drug failed a clinical trial.

Its commercial product is Relyvrio, also known as Albrioza in Canada. The company was founded by Joshua Cohen and Justin Klee in 2013 and is headquartered in Cambridge, MA.